

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. IOM Health System, LP d/b/a Lutheran Hospital of Indiana 2. 7950 West Jefferson Blvd. Fort Wayne, IN 46804		In accordance with letter dated December 10, 2021,	4. Expiration Date: August 31, 2025
		3. License No.: 13-01535-01 is amended in its entirety to read as follows:	5. Docket No.: 030-01594 Reference No.:
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-01535-01

Docket or Reference No.:
030-01594

Amendment No. 81

- | | | | |
|---|--|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| D. Iodine-125 permitted by 10 CFR 35.400 | D. Sealed sources (Bard, Model Model STM1251; Best Industries, Model Model 2301; Implant Sciences Corp., Model I-Plant Model 3500; IsoAid, LLC, Model Model IAI-125A; Mills Biopharmaceuticals, Inc., Model Model SL-125; SH-125; North American Scientific, Inc., Model Model MED 3631) | D. 1 curie total | D. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| E. Palladium-103 permitted by 10 CFR 35.400 | E. Sealed sources (Best Medical International Inc., Model 2335; North American Scientific, Inc., Model MED 3633; Theragenics Corp., Model TheraSeed 200) | E. 1 curie total | E. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| F. Cesium-131 permitted by 10 CFR 35.400 | F. Sealed Sources (IsoRay Medical Inc., Model CS-1) | F. 1 curie total | F. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| G. Any byproduct material permitted by 10 CFR 31.11 | G. Prepackaged kits | G. 1 millicurie total | G. For use in in-vitro studies. |
| H. Yttrium-90 permitted by 10 CFR 35.1000 | H. Microspheres (AEA Technology/QSA, Inc., Model SIR-Spheres) | H. Not to exceed 189 millicuries per vial and 2 curies total | H. For medical use permitted by 10 CFR 35.1000 in a Sirtex Medical Limited brachytherapy afterloader delivery system. |
| I. Yttrium-90 permitted by 10 CFR 35.1000 | I. Microspheres (MDS Nordion, Model TheraSphere) | I. 3 curies total | I. For medical use permitted by 10 CFR 35.1000 in an MDS Nordion TheraSphere brachytherapy delivery system. |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-01535-01

Amendment No. 81

Docket or Reference No.:
030-01594**CONDITIONS**

10. A. Licensed material may be used or stored at the licensee's facilities located at 7950 West Jefferson Boulevard, Fort Wayne, Indiana.
- B. Licensed material listed in Item Nos. 6.A. and 6.B. may be used at the licensee's facilities located at 7916 West Jefferson Boulevard, Fort Wayne, Indiana.
11. The Radiation Safety Officer (RSO) for this license is Randall J. Phillips, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users

Sanjiv G. Aggarwal, M.D.

James A. Arata, M.D.

Andrew V. Barger, M.D.

Jonathan Berger, M.D.

John L. Borman, M.D.

Daniel Branam, M.D.

Nathan A. Cannon, M.D., Ph.D.

Andrew Ceranske, M.D.

Nathan D. Comsia, M.D.

Material and Use

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200, 35.300 and 31.11

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33mci)

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200 and 35.300

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.400

10 CFR 35.100, 35.200 and 35.1000 (limited to the yttrium-90 TheraSpheres delivery system)

10 CFR 35.400

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-01535-01

Docket or Reference No.:
030-01594

Amendment No. 81

Authorized Users

Joseph R. Decamp, M.D.

Brett A. Hagedorn, M.D.

Eric V. Heatwole, M.D.

Joel Heitman, M.D.

Saad M. Ibrahim, M.D.

David B. Janizek, M.D.

Christopher M. Kowalski, M.D.

Jonathan M. Lee, M.D.

John C. Lucunza, M.D.

Rao V.P. Mantravadi, M.D.

Scott E. Mattson, D.O.

Indu Rekha Meesa, M.D.

Mark A. Meier, M.D.

Michael E. Parker, M.D.

John Pasalich, M.D.

Dakshesh S. Patel, M.D.

Randall J. Phillips, M.D.

Venkata Rama Prasad Nalamolu,
M.D.

Krishnan Ramani, M.D.

Mark C. Ranck, M.D.

John Rock, M.D.

Material and Use

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 35.200 and 35.300

10 CFR 35.100 and 35.200

10 CFR 35.100 and 35.200

10 CFR 35.1000 (limited to the yttrium-90 SIR-Spheres delivery system and the yttrium-90 TheraSpheres delivery system)

10 CFR 35.100, 35.200, 35.300 and 31.11

10 CFR 35.100 and 35.200

10 CFR 35.300 (limited to the oral administration of sodium iodide I-131) and 35.1000 (limited to the yttrium-90 TheraSpheres delivery system)

10 CFR 35.100 and 35.200

10 CFR 35.300 and 35.400

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.200

10 CFR 35.100, 35.200 and 35.300

10 CFR 35.100, 35.200 and 35.300

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200, 35.300, 35.1000 (limited to the yttrium-90 SIR-Spheres delivery system) and 31.11

10 CFR 35.200

10 CFR 35.200

10 CFR 35.400

10 CFR 35.100, 35.200 and 31.11

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-01535-01

Docket or Reference No.:
030-01594

Amendment No. 81

Authorized Users

Wesley A. Russell, M.D.

Vivek Sharma, M.D.

Eugene Shih, M.D.

Richard W. Sibley, M.D.

Rik Stephens, M.D.

Andre Byard Stovall, M.D.

Pamela Lee Strange, M.D.

Marc Thomas, M.D.

Benjamin A. Tourkow, M.D.

Edward K. Yi, M.D.

Material and Use

10 CFR 35.400

10 CFR 35.100 and 35.200

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200 and 35.300

10 CFR 35.100, 35.200, 35.300 and 31.11

10 CFR 35.100, 35.200, 35.300, and 35.1000 (limited to the yttrium-90 SIR-Spheres delivery system)

10 CFR 35.100, 35.200 and 35.300

10 CFR 35.100, 35.200 and 35.300

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 13-01535-01

Amendment No. 81

Docket or Reference No.:
030-01594

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated May 12, 2015 (ML15146A271)
- B. Letter dated May 12, 2015 (ML15146A271)
- C. Letter dated June 18, 2015 (ML15175A296)
- D. Letter dated February 17, 2017 (ML17201J344)
- E. Letter dated September 3, 2019 (ML19248C703)
- F. Letter dated April 13, 2020 (ML20107J534)
- G. Letter dated July 28, 2020 (ML20217L341)



FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date: March 2, 2022By: _____
Bryan A. Parker
Region III